Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 65

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 65
---
 2024 (Unaudited)

The following table summarizes our condensed consolidated results of operations for the periods indicated, together with the changes in those items in terms of dollars and percentage:

Three Months Ended March 31,Change20252024$%Revenues:Royalty revenue$25,427 $9,302 $16,125 173 %Total revenue25,427 9,302 16,125 173 %Operating expenses:General and administrative 2,309,164 2,670,581 (361,417)(14)%Research and development 2,297,381 3,353,520 (1,056,139)(31)%Royalty expense— 7,674 (7,674)— %Total operating expenses4,606,545 6,031,775 (1,425,230)(24)%Loss from operations(4,581,118)(6,022,473)1,441,355 (24)%Other income (expense)202,811 (732,883)935,694 (128)%Net loss$(4,378,307)$(6,755,356)$2,377,049 (35)%Other comprehensive loss:Foreign currency translation adjustments13,090 (39,227)52,317 (133)%Comprehensive loss$(4,365,217)$(6,794,583)$2,429,366 (36)%

Revenues

Revenues for the three months ended March 31, 2025 and March 31, 2024 are related to our license agreement with Organon to commercialize XACIATO. From and after April 1, 2024, any revenue we recognize under such license agreement will be recognized as non-cash royalty revenue. See "—Financial Overview—Revenue," above for information.

General and administrative expenses

The decrease of approximately $0.4 million in general and administrative expenses for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024 was primarily attributable to decreases in (i) stock-based compensation expense of approximately $0.2 million, (ii) professional services expense of approximately $0.1 million, and (iii) personnel costs of approximately $0.1 million. 

Research and development expenses

The following table summarizes our R&D expenses for the periods indicated, together with the changes in those items in terms of dollars